Antitumor effects of Andrographis via ferroptosis‑associated genes in gastric cancer
- Authors:
- Ruiya Ma
- Tadanobu Shimura
- Chengzeng Yin
- Yoshinaga Okugawa
- Takahito Kitajima
- Yuhki Koike
- Yoshiki Okita
- Masaki Ohi
- Keiichi Uchida
- Ajay Goel
- Li Yao
- Xueming Zhang
- Yuji Toiyama
-
Affiliations: Department of Gastrointestinal and Pediatric Surgery, Institute of Life Sciences, Mie University Graduate School of Medicine, Tsu, Mie 514‑8507, Japan, Department of Genomic Medicine, Mie University Hospital, Tsu, Mie 514‑8507, Japan, Department of Molecular Diagnostics and Experimental Therapeutics, Beckman Research Institute, City of Hope Comprehensive Cancer Center, Duarte, CA 91016, USA, Department of Surgery, China‑Japan Friendship Hospital, Beijing 100029, P.R. China, Department of Colorectal Surgery, Tangshan Gongren Hospital, Tangshan, Hebei 063000, P.R. China - Published online on: May 12, 2021 https://doi.org/10.3892/ol.2021.12784
- Article Number: 523
This article is mentioned in:
Abstract
 |
 |
 |
|
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018.Erratum in: CA Cancer J Clin 70: 313, 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Digklia A and Wagner AD: Advanced gastric cancer: Current treatment landscape and future perspectives. World J Gastroenterol. 22:2403–2414. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Smyth EC, Nilsson M, Grabsch HI, van Grieken NC and Lordick F: Gastric cancer. Lancet. 396:635–648. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Hironaka S, Sugimoto N, Yamaguchi K, Moriwaki T, Komatsu Y, Nishina T, Tsuji A, Nakajima TE, Gotoh M, Machida N, et al: S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: A randomised, multicentre, open-label, phase 2 trial. Lancet Oncol. 17:99–108. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Wagner AD, Syn NL, Moehler M, Grothe W, Yong WP, Tai BC, Ho J and Unverzagt S: Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 8:CD0040642017.PubMed/NCBI | |
|
Van Cutsem E, Sagaert X, Topal B, Haustermans K and Prenen H: Gastric cancer. Lancet. 388:2654–2664. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Muro K, Van Cutsem E, Narita Y, Pentheroudakis G, Baba E, Li J, Ryu MH, Zamaniah WIW, Yong WP, Yeh KH, et al: Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: A JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Ann Oncol. 30:19–33. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Hyodo I, Amano N, Eguchi K, Narabayashi M, Imanishi J, Hirai M, Nakano T and Takashima S: Nationwide survey on complementary and alternative medicine in cancer patients in Japan. J Clin Oncol. 23:2645–2654. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Chan A, Tan HL, Ching TH and Tan HC: Clinical outcomes for cancer patients using complementary and alternative medicine. Altern Ther Health Med. 18:12–17. 2012.PubMed/NCBI | |
|
Liu TG, Xiong SQ, Yan Y, Zhu H and Yi C: Use of chinese herb medicine in cancer patients: a survey in southwestern china. Evid Based Complement Alternat Med. 2012:7690422012. View Article : Google Scholar : PubMed/NCBI | |
|
Newman DJ and Cragg GM: Natural products as sources of new drugs from 1981 to 2014. J Nat Prod. 79:629–661. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Singh S, Pandey P, Ghosh S and Banerjee S: Anti-cancer labdane diterpenoids from adventitious roots of Andrographis paniculata: Augmentation of production prospect endowed with pathway gene expression. Protoplasma. 255:1387–1400. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Islam MT, Ali ES, Uddin SJ, Islam MA, Shaw S, Khan IN, Saravi SSS, Ahmad S, Rehman S, Gupta VK, et al: Andrographolide, a diterpene lactone from Andrographis paniculata and its therapeutic promises in cancer. Cancer Lett. 420:129–145. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Liu G and Chu H: Andrographolide inhibits proliferation and induces cell cycle arrest and apoptosis in human melanoma cells. Oncol Lett. 15:5301–5305. 2018.PubMed/NCBI | |
|
Suo XB, Zhang H and Wang YQ: HPLC determination of andrographolide in rat whole blood: Study on the pharmacokinetics of andrographolide incorporated in liposomes and tablets. Biomed Chromatogr. 21:730–734. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Lu WJ, Lee JJ, Chou DS, Jayakumar T, Fong TH, Hsiao G and Sheu JR: A novel role of andrographolide, an NF-kappa B inhibitor, on inhibition of platelet activation: The pivotal mechanisms of endothelial nitric oxide synthase/cyclic GMP. J Mol Med (Berl). 89:1261–1273. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Jayakumar T, Hsieh CY, Lee JJ and Sheu JR: Experimental and clinical pharmacology of Andrographis paniculata and its major bioactive phytoconstituent andrographolide. Evid Based Complement Alternat Med. 2013:8467402013. View Article : Google Scholar : PubMed/NCBI | |
|
Poolsup N, Suthisisang C, Prathanturarug S, Asawamekin A and Chanchareon U: Andrographis paniculata in the symptomatic treatment of uncomplicated upper respiratory tract infection: Systematic review of randomized controlled trials. J Clin Pharm Ther. 29:37–45. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Dai Y, Chen SR, Chai L, Zhao J and Wang Y and Wang Y: Overview of pharmacological activities of Andrographis paniculata and its major compound andrographolide. Crit Rev Food Sci Nutr. 59 (Suppl 1):S17–S29. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Kumar D, Das B, Sen R, Kundu P, Manna A, Sarkar A, Chowdhury C, Chatterjee M and Das P: Andrographolide analogue induces apoptosis and autophagy mediated cell death in U937 cells by inhibition of PI3K/Akt/mTOR pathway. PLoS One. 10:e01396572015. View Article : Google Scholar : PubMed/NCBI | |
|
Li L, Yue GG, Lee JK, Wong EC, Fung KP, Yu J, Lau CB and Chiu PW: The adjuvant value of Andrographis paniculata in metastatic esophageal cancer treatment - from preclinical perspectives. Sci Rep. 7:8542017. View Article : Google Scholar : PubMed/NCBI | |
|
Banerjee M, Chattopadhyay S, Choudhuri T, Bera R, Kumar S, Chakraborty B and Mukherjee SK: Cytotoxicity and cell cycle arrest induced by andrographolide lead to programmed cell death of MDA-MB-231 breast cancer cell line. J Biomed Sci. 23:402016. View Article : Google Scholar : PubMed/NCBI | |
|
Lai YH, Yu SL, Chen HY, Wang CC, Chen HW and Chen JJ: The HLJ1-targeting drug screening identified Chinese herb andrographolide that can suppress tumour growth and invasion in non-small-cell lung cancer. Carcinogenesis. 34:1069–1080. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Li Y, Zhang P, Qiu F, Chen L, Miao C, Li J, Xiao W and Ma E: Inactivation of PI3K/Akt signaling mediates proliferation inhibition and G2/M phase arrest induced by andrographolide in human glioblastoma cells. Life Sci. 90:962–967. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Yuan M, Meng W, Liao W and Lian S: Andrographolide antagonizes TNF-α-induced IL-8 via inhibition of NADPH oxidase/ROS/NF-κB and Src/MAPKs/AP-1 axis in human colorectal cancer HCT116 cells. J Agric Food Chem. 66:5139–5148. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang R, Zhao J, Xu J, Jiao DX, Wang J, Gong ZQ and Jia JH: Andrographolide suppresses proliferation of human colon cancer SW620 cells through the TLR4/NF-κB/MMP-9 signaling pathway. Oncol Lett. 14:4305–4310. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Deng Y, Bi R, Guo H, Yang J, Du Y, Wang C and Wei W: Andrographolide enhances TRAIL-induced apoptosis via p53-mediated death receptors up-regulation and suppression of the NF-кB pathway in bladder cancer cells. Int J Biol Sci. 15:688–700. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Bao GQ, Shen BY, Pan CP, Zhang YJ, Shi MM and Peng CH: Andrographolide causes apoptosis via inactivation of STAT3 and Akt and potentiates antitumor activity of gemcitabine in pancreatic cancer. Toxicol Lett. 222:23–35. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Yang W, Zhao J, Wang Y, Xu H, Wu Z, Hu Y, Jiang K, Shen P, Ma C, Guan Z, et al: In vivo inhibitory activity of andrographolide derivative ADN-9 against liver cancer and its mechanisms involved in inhibition of tumor angiogenesis. Toxicol Appl Pharmacol. 327:1–12. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Lim JC, Chan TK, Ng DS, Sagineedu SR, Stanslas J and Wong WS: Andrographolide and its analogues: Versatile bioactive molecules for combating inflammation and cancer. Clin Exp Pharmacol Physiol. 39:300–310. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Yue GG, Li L, Lee JK, Kwok HF, Wong EC, Li M, Fung KP, Yu J, Chan AW, Chiu PW and Lau CB: Multiple modulatory activities of Andrographis paniculata on immune responses and xenograft growth in esophageal cancer preclinical models. Phytomedicine. 60:1528862019. View Article : Google Scholar : PubMed/NCBI | |
|
Lim SC, Jeon HJ, Kee KH, Lee MJ, Hong R and Han SI: Andrographolide induces apoptotic and non-apoptotic death and enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in gastric cancer cells. Oncol Lett. 13:3837–3844. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Stewart MJ and Watson ID: Standard units for expressing drug concentrations in biological fluids. Br J Clin Pharmacol. 16:3–7. 1983. View Article : Google Scholar : PubMed/NCBI | |
|
Takahashi M, Sung B, Shen Y, Hur K, Link A, Boland CR, Aggarwal BB and Goel A: Boswellic acid exerts antitumor effects in colorectal cancer cells by modulating expression of the let-7 and miR-200 microRNA family. Carcinogenesis. 33:2441–2449. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Schneider CA, Rasband WS and Eliceiri KW: NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 9:671–675. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Li SG, Wang YY, Ye ZY, Shao QS, Tao HQ, Shu LS, Zhao YF, Yang YJ, Yang J, Peng T, et al: Proliferative and apoptotic effects of andrographolide on the BGC-823 human gastric cancer cell line. Chin Med J (Engl). 126:3739–3744. 2013.PubMed/NCBI | |
|
Dai L, Wang G and Pan W: Andrographolide inhibits proliferation and metastasis of SGC7901 gastric cancer cells. BioMed Res Int. 2017:62421032017. View Article : Google Scholar : PubMed/NCBI | |
|
Yu AL, Lu CY, Wang TS, Tsai CW, Liu KL, Cheng YP, Chang HC, Lii CK and Chen HW: Induction of heme oxygenase 1 and inhibition of tumor necrosis factor alpha-induced intercellular adhesion molecule expression by andrographolide in EA.hy926 cells. J Agric Food Chem. 58:7641–7648. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Seo JY, Pyo E, An JP, Kim J, Sung SH and Oh WK: Andrographolide activates Keap1/Nrf2/ARE/HO-1 pathway in HT22 cells and suppresses microglial activation by Aβ42 through Nrf2-related inflammatory response. Mediators Inflamm. 2017:59061892017. View Article : Google Scholar : PubMed/NCBI | |
|
Lu CY, Yang YC, Li CC, Liu KL, Lii CK and Chen HW: Andrographolide inhibits TNFα-induced ICAM-1 expression via suppression of NADPH oxidase activation and induction of HO-1 and GCLM expression through the PI3K/Akt/Nrf2 and PI3K/Akt/AP-1 pathways in human endothelial cells. Biochem Pharmacol. 91:40–50. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Lee JC, Tseng CK, Young KC, Sun HY, Wang SW, Chen WC, Lin CK and Wu YH: Andrographolide exerts anti-hepatitis C virus activity by up-regulating haeme oxygenase-1 via the p38 MAPK/Nrf2 pathway in human hepatoma cells. Br J Pharmacol. 171:237–252. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Guan SP, Tee W, Ng DS, Chan TK, Peh HY, Ho WE, Cheng C, Mak JC and Wong WS: Andrographolide protects against cigarette smoke-induced oxidative lung injury via augmentation of Nrf2 activity. Br J Pharmacol. 168:1707–1718. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Chao CY, Lii CK, Hsu YT, Lu CY, Liu KL, Li CC and Chen HW: Induction of heme oxygenase-1 and inhibition of TPA-induced matrix metalloproteinase-9 expression by andrographolide in MCF-7 human breast cancer cells. Carcinogenesis. 34:1843–1851. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Kwon MY, Park E, Lee SJ and Chung SW: Heme oxygenase-1 accelerates erastin-induced ferroptotic cell death. Oncotarget. 6:24393–24403. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Sharma P, Shimura T, Banwait JK and Goel A: Andrographis-mediated chemosensitization through activation of ferroptosis and suppression of β-catenin/Wnt-signaling pathways in colorectal cancer. Carcinogenesis. 41:1385–1394. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Yang G, Li X, Li X, Wang L, Li J, Song X, Chen J, Guo Y, Sun X, Wang S, et al: Traditional chinese medicine in cancer care: a review of case series published in the chinese literature. Evid Based Complement Alternat Med. 2012:7510462012. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou J, Ong CN, Hur GM and Shen HM: Inhibition of the JAK-STAT3 pathway by andrographolide enhances chemosensitivity of cancer cells to doxorubicin. Biochem Pharmacol. 79:1242–1250. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Liang C, Zhang X, Yang M and Dong X: Recent progress in ferroptosis inducers for cancer therapy. Adv Mater. 31:e19041972019. View Article : Google Scholar : PubMed/NCBI | |
|
Ye Z, Liu W, Zhuo Q, Hu Q, Liu M, Sun Q, Zhang Z, Fan G, Xu W, Ji S, et al: Ferroptosis: Final destination for cancer? Cell Prolif. 53:e127612020. View Article : Google Scholar : PubMed/NCBI | |
|
Hassannia B, Vandenabeele P and Vanden Berghe T: Targeting Ferroptosis to Iron Out Cancer. Cancer Cell. 35:830–849. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Yu Y, Xie Y, Cao L, Yang L, Yang M, Lotze MT, Zeh HJ, Kang R and Tang D: The ferroptosis inducer erastin enhances sensitivity of acute myeloid leukemia cells to chemotherapeutic agents. Mol Cell Oncol. 2:e10545492015. View Article : Google Scholar : PubMed/NCBI | |
|
Yang S, Evens AM, Prachand S, Singh AT, Bhalla S, David K and Gordon LI: Mitochondrial-mediated apoptosis in lymphoma cells by the diterpenoid lactone andrographolide, the active component of Andrographis paniculata. Clin Cancer Res. 16:4755–4768. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Xia X, Fan X, Zhao M and Zhu P: The relationship between ferroptosis and tumors: a novel landscape for therapeutic approach. Curr Gene Ther. 19:117–124. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Chen Y, Fan Z, Yang Y and Gu C: Iron metabolism and its contribution to cancer (Review). Int J Oncol. 54:1143–1154. 2019.PubMed/NCBI | |
|
Roh JL, Kim EH, Jang HJ, Park JY and Shin D: Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer. Cancer Lett. 381:96–103. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Louandre C, Ezzoukhry Z, Godin C, Barbare JC, Mazière JC, Chauffert B and Galmiche A: Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib. Int J Cancer. 133:1732–1742. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Puntawee S, Theerasilp M, Reabroi S, Saeeng R, Piyachaturawat P, Chairoungdua A and Nasongkla N: Solubility enhancement and in vitro evaluation of PEG-b-PLA micelles as nanocarrier of semi-synthetic andrographolide analogue for cholangiocarcinoma chemotherapy. Pharm Dev Technol. 21:437–444. 2016.PubMed/NCBI | |
|
Basuli D, Tesfay L, Deng Z, Paul B, Yamamoto Y, Ning G, Xian W, McKeon F, Lynch M, Crum CP, et al: Iron addiction: A novel therapeutic target in ovarian cancer. Oncogene. 36:4089–4099. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Eling N, Reuter L, Hazin J, Hamacher-Brady A and Brady NR: Identification of artesunate as a specific activator of ferroptosis in pancreatic cancer cells. Oncoscience. 2:517–532. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Q and Wang K: The induction of ferroptosis by impairing STAT3/Nrf2/GPx4 signaling enhances the sensitivity of osteosarcoma cells to cisplatin. Cell Biol Int. 43:1245–1256. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Li Y, Yan H, Xu X, Liu H, Wu C and Zhao L: Erastin/sorafenib induces cisplatin-resistant non-small cell lung cancer cell ferroptosis through inhibition of the Nrf2/xCT pathway. Oncol Lett. 19:323–333. 2020.PubMed/NCBI | |
|
Sugiyama A, Ohta T, Obata M, Takahashi K, Seino M and Nagase S: xCT inhibitor sulfasalazine depletes paclitaxel-resistant tumor cells through ferroptosis in uterine serous carcinoma. Oncol Lett. 20:2689–2700. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Bussolati B, Ahmed A, Pemberton H, Landis RC, Di Carlo F, Haskard DO and Mason JC: Bifunctional role for VEGF-induced heme oxygenase-1 in vivo: Induction of angiogenesis and inhibition of leukocytic infiltration. Blood. 103:761–766. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Farombi EO and Surh YJ: Heme oxygenase-1 as a potential therapeutic target for hepatoprotection. J Biochem Mol Biol. 39:479–491. 2006.PubMed/NCBI | |
|
Jozkowicz A, Was H and Dulak J: Heme oxygenase-1 in tumors: Is it a false friend? Antioxid Redox Signal. 9:2099–2117. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Chiang SK, Chen SE and Chang LC: A Dual Role of Heme Oxygenase-1 in Cancer Cells. Int J Mol Sci. 20:202018. View Article : Google Scholar | |
|
Trachootham D, Alexandre J and Huang P: Targeting cancer cells by ROS-mediated mechanisms: A radical therapeutic approach? Nat Rev Drug Discov. 8:579–591. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Suttner DM and Dennery PA: Reversal of HO-1 related cytoprotection with increased expression is due to reactive iron. FASEB J. 13:1800–1809. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Chang LC, Chiang SK, Chen SE, Yu YL, Chou RH and Chang WC: Heme oxygenase-1 mediates BAY 11-7085 induced ferroptosis. Cancer Lett. 416:124–137. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Chau LY: Heme oxygenase-1: Emerging target of cancer therapy. J Biomed Sci. 22:222015. View Article : Google Scholar : PubMed/NCBI | |
|
Hill M, Pereira V, Chauveau C, Zagani R, Remy S, Tesson L, Mazal D, Ubillos L, Brion R, Asghar K, et al: Heme oxygenase-1 inhibits rat and human breast cancer cell proliferation: Mutual cross inhibition with indoleamine 2,3-dioxygenase. FASEB J. 19:1957–1968. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Ferrando M, Gueron G, Elguero B, Giudice J, Salles A, Leskow FC, Jares-Erijman EA, Colombo L, Meiss R, Navone N, et al: Heme oxygenase 1 (HO-1) challenges the angiogenic switch in prostate cancer. Angiogenesis. 14:467–479. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Nishizawa H, Matsumoto M, Shindo T, Saigusa D, Kato H, Suzuki K, Sato M, Ishii Y, Shimokawa H and Igarashi K: Ferroptosis is controlled by the coordinated transcriptional regulation of glutathione and labile iron metabolism by the transcription factor BACH1. J Biol Chem. 295:69–82. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Lu SC: Glutathione synthesis. Biochim Biophys Acta. 1830:3143–3153. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Huang CS, Lii CK, Lin AH, Yeh YW, Yao HT, Li CC, Wang TS and Chen HW: Protection by chrysin, apigenin, and luteolin against oxidative stress is mediated by the Nrf2-dependent up-regulation of heme oxygenase 1 and glutamate cysteine ligase in rat primary hepatocytes. Arch Toxicol. 87:167–178. 2013. View Article : Google Scholar : PubMed/NCBI |
